After SCT in childhood, survivors may develop disorders of glucose metabolism. The role of obesity is controversial. We measured insulin sensitivity using the homeostasis model assessment (HOMA) and the frequently sampled i.v. glucose tolerance test (FSIVGTT), as well as body composition using dual-energy X-ray absorptiometry in 18 young adults median 18.2 years after SCT and compared them with matched controls. We also measured growth hormone (GH) secretion, and levels of leptin and adiponectin. HOMA showed insulin resistance in eight patients (44%), as opposed to none of the controls (P ¼ 0.008) and FSIVGTT showed a decreased sensitivity index in the patients (2.98 vs 4.54 mU/L/min, P ¼ 0.042). Dual energy X-ray absorptiometry showed a higher percentage fat mass in the patients (34.9 vs 24.3%, P ¼ 0.011), which correlated inversely with the sensitivity index (r ¼ À0.52, P ¼ 0.032). The patients had a lower peak value of GH (GH max 9 vs 20.7 mU/L, P ¼ 0.002). Time post SCT correlated with percentage fat mass and inversely with GH max . The patients had higher levels of leptin and lower levels of adiponectin, even after adjustment for fat mass. We propose that the decreased insulin sensitivity may primarily be explained by the adverse body composition, which may owe to long-standing GH deficiency.
Introduction
Long-term SCT survivors, particularly those who received TBI as part of their conditioning, have an increased risk of developing impaired glucose metabolism, notably insulin resistance, and also impaired glucose tolerance and diabetes mellitus. [1] [2] [3] [4] [5] [6] [7] [8] In the general population, insulin resistance with its metabolic consequences is closely related to obesity. 9 However, as most SCT survivors are normal-or underweight when assessed with body mass index (BMI), there is no obvious relationship between insulin resistance and obesity in this group. 10 This would suggest that other contributing factors, such as radiation-induced b-cell dysfunction or dysregulation of growth hormone (GH) and adipokine secretion may be more important. 5, 8, 11, 12 On the other hand, BMI may not necessarily reflect body composition and may be an unreliable measure of obesity in SCT survivors. 13 The present cross-sectional study investigates glucose metabolism and body composition in 18 young adults treated with SCT and TBI for hematologic malignancies in childhood with a median follow-up of 18 years.
Patients and methods

Patients
We aimed to investigate long-term transplant survivors (defined here as being alive 10 years after SCT) treated with TBI for ALL or lymphoblastic lymphoma (these malignancies are treated similarly). Between the start of the pediatric SCT program at the University Hospital of Uppsala in October 1985 till June 1999 (that is, 10 years before conclusion of the present study in June 2009), 45 children under 18 years of age, and one patient who was 18.3 years, with ALL (n ¼ 43) or lymphoblastic lymphoma (n ¼ 3) were treated with auto-(n ¼ 31), syngeneic (n ¼ 1) or allo-(n ¼ 14) SCT including TBI. Of these, 29 are alive today (autologous/syngeneic, n ¼ 22, allogeneic, n ¼ 7). In order to create as homogenous a study group as possible, we avoided the possible effects of puberty and GVHD on insulin sensitivity. Therefore, only patients who had reached final height and had undergone auto-SCT, or allo-SCT with no chronic GVHD, were included. Three patients with chronic GVHD and one patient who had not reached final height were excluded. Twenty-five patients were subsequently invited to participate (autologous/ syngeneic, n ¼ 22, allogeneic, n ¼ 3). One female and six male invitees declined participation in the study, resulting in a study group of fifteen autografted patients and three recipients of an allogeneic graft (Table 1) . Only one female patient cited a late complication as cause for nonparticipation (pending surgery for a meningioma).
The patients had been treated according to the leukemia protocol that applied at the time of diagnosis.
14 Seven patients had received cranial radiation therapy of 18-26 Gy (median 24 Gy) and three males had received radiation to the testes (16, 21 and 32 Gy, respectively). Details of the conditioning regimen have been thoroughly presented elsewhere. 15 Briefly, patients were conditioned with a CY-based chemotherapy regimen plus TBI, given in most children (n ¼ 12) as a single fraction of 7.5 Gy as two opposed 5 MV X-ray anterior-posterior fields with lung shielding. The six patients most recently undergoing transplantation were treated with fractionated TBI, consisting of 12.6 Gy in six fractions over 3 days. GVHD prophylaxis consisted of short-term MTX and CYA, which was tapered over 6 months.
Nine patients had received GH treatment following SCT (median 3.6 years, range 2.0-4.8 years), which was discontinued at attainment of final height. One female was started on GH treatment 2 years after SCT and was still receiving treatment at the time of the study and was excluded from analyses including GH. Nine patients with subclinical hypothyroidism were receiving thyroxine substitution; all patients had normal thyroxine levels at the time of the study. Four males and four females were receiving sex hormone replacement therapy. Untreated primary hypogonadism (testosterone o10 nmol/L or estradiol o100 pmol/L with concomitant supranormal gonadotrophin concentration) was documented in one male and three females. Two females had undergone surgery for a meningioma 1 1 2 and 3 years before the study, respectively. The former had also received adjuvant proton therapy of 28 Gy. One female had had a sinus thrombosis 8 years before the study and was receiving dicumarol. One male had hypertension and hyperuricemia and was treated with enalapril and allopurinol. One female was a smoker.
Control subjects
In order to select one age-and sex-matched control subject for each patient, letters were sent to 10 potential control subjects for each patient, randomly selected from a computerized register of the population in Uppsala County. Of those who accepted by mail, the first who replied to a phone call and was deemed eligible for the study was chosen (no known diseases, no medication other than contraceptives, no current pregnancy, no smoking). If none of the 10 selected control subjects accepted, a new set of 10 controls was selected and the process was repeated (Table 1) .
Study protocol
All investigations were performed on two consecutive days and one night. Blood samples for insulin, C-peptide, insulin-like growth factor 1, insulin-like growth factorbinding protein 3, highly sensitive C-reactive protein, leptin and adiponectin were collected in the day 1 morning after a 12 h overnight fast. This was followed by an oral glucose tolerance test; all subjects were given 75 g glucose and samples for measurement of glucose were drawn at baseline and at 30, 60, 90 and 120 min. Impaired glucose tolerance was defined as fasting plasma glucose X 5.6 mmol/L or X7.8 mmol/L at 120 min. The frequently sampled i.v. glucose tolerance test (FSIVGTT) was performed on day 2 after a 12 h overnight fast. An i.v. catheter was inserted in each arm. Four fasting baseline samples for glucose and insulin were drawn at the time À15, À10, À5 and 0 min. At time 1 min, 0.3 g glucose per kilogram body weight was given intravenously as 30% dextrose over a period of 1 min. At 20 min, 0.02 U insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) per kilogram body weight was given as an i.v. bolus dose. To determine glucose and insulin levels, blood samples were drawn at 0, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 25, 30, 40, 50, 60, 70, 80, 90 , 100, 120, 140, 160 and 180 min. Insulin in pmol/L was converted to mU/L using the conversion factor 1/6.945. 16 For calculations, the minimal model computer program (MINMOD Millenium) was used. 17 Insulin sensitivity was also estimated by the homeostasis model assessment (HOMA) index, calculated using the formula; fasting insulin Â fasting glucose/22.5.
18
A HOMA index of 42.86 was considered to indicate insulin resistance. 19 Height and weight were measured in the morning. BMI was calculated as body mass in kilograms divided by the height squared in meters (kg/ m 2 ). Waist circumference was measured by the same investigator (PF) as the horizontal circumference in the standing position at the level midway between the lowest rib and the iliac crest. Central obesity was defined according to the International Diabetes Federation criteria as waist circumference X94 cm in men and X80 cm in women. 20 Dual energy X-ray absorptiometry (Lunar Radiation, Madison, WI, USA) was used to measure fat mass and lean body mass. Fat mass and lean body mass are presented in kilograms and fat mass is also presented as percentage of body weight. Spontaneous GH secretion was measured by blood sampling every 30 min during the night 
Results
Comparisons of patients with controls
Compared with the control group, patients had significantly higher fasting insulin, C-peptide and HOMA index ( Table 2) . Eight patients (44%), as opposed to none of the controls, had a HOMA index 42.86 (P ¼ 0.008).
FSIVGTT showed a lower sensitivity index and a higher acute insulin response in the patient group. There were no differences in disposition index, fasting glucose or glucose at 120 min in the oral glucose tolerance test. Impaired glucose tolerance was recorded in four patients (22%) and in three controls (17%). The patients were shorter than the controls. BMI tended to be lower and fat mass higher among the patients, but these differences did not reach statistical significance. The percentage fat mass was significantly higher and lean body mass was significantly lower in the patient group. Five patients (28%) and eight controls (44%) were overweight (BMI X25) (P ¼ 0.25). Among these, the median percentage fat mass was 42.9 in the patient group (three males) and 29.5 in the control group (four males, P ¼ 0.062). There was no difference between the groups in waist circumference. Five patients and five controls were centrally obese according to the International Diabetes Federation criteria.
GH max was significantly lower among the patients, but there was no difference in serum levels of insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. (Table 3 ) We recorded significantly higher levels of C-reactive protein and leptin, and significantly lower levels of adiponectin in the patients, even after adjustment for fat mass.
Comparisons among patients
In categorical analyses, a HOMA index of 42.86 was associated with BMI X25 (5/8 vs 0/10, P ¼ 0.007) and central obesity (6/8 vs 1/10, P ¼ 0.013). Sensitivity index correlated inversely with percentage fat mass (r ¼ À0.52, P ¼ 0.032) but not with waist circumference (r ¼ À0.43, P ¼ 0.077). We found no correlation between the sensitivity index (r ¼ À0.01, P ¼ 0.96) or the disposition index (r ¼ 0.12, P ¼ 0.63) and post-SCT.
GH max correlated inversely with percentage fat mass (r ¼ À0.63, P ¼ 0.009) but not with the sensitivity index (r ¼ 0.26, P ¼ 0.31). GH max correlated negatively (r ¼ À0.62, P ¼ 0.008) and percentage fat mass correlated positively (r ¼ 0.51, P ¼ 0.037) with time post SCT.
We found no correlation between the sensitivity index and leptin (r ¼ À0.29, P ¼ 0.27) or adiponectin (r ¼ 0.16, P ¼ 0.55) after adjustment for fat mass.
Discussion
We present the first study of insulin sensitivity in SCT survivors in which FSIVGTT was used and in which insulin sensitivity was correlated with body composition measured with dual energy X-ray absorptiometry. FSIVGTT affords an accurate measurement of insulin sensitivity and also of b-cell function, which could be compromised in the long-term after TBI. 22 Compared with controls, we found higher fasting insulin and C-peptide levels and a high prevalence of insulin resistance in the patients (in 44% assessed with HOMA). The lower insulin sensitivity in the patients was offset by increased insulin secretion, resulting in the maintenance of glucose homeostasis in most patients and a prevalence of impaired glucose tolerance similar to that of the controls. Our results are in line with those reported by Lorini et al, who performed i.v. glucose tolerance tests and measured C-peptide response after i.v. glucagon in SCT patients, 18 of whom had received TBI. 1 The lack of correlation between the disposition index and time after SCT in the present study indicates that b-cell function did not deteriorate during the time frame of the study, which represents the longest follow-up to date (median 18 years after SCT).
Taskinen et al found insulin resistance (assessed with HOMA) in 18 of 31 (58%) SCT survivors, 28 of whom had received TBI, and Neville et al reported hyperinsulinemia, impaired glucose tolerance or diabetes mellitus (grouped together) in 64% of SCT survivors treated with TBI, that is, higher prevalences than in our study. 3, 5 In addition, Taskinen et al documented impaired glucose tolerance in 13 out of the 31 patients (42%), including three with type 2 diabetes mellitus, a much higher prevalence of disturbed glucose homeostasis than that in the present study. These differences are not easily explained. Among previously reported risk factors for insulin resistance and disturbed glucose homeostasis after SCT, notably TBI, abdominal obesity, untreated hypogonadism, growth hormone deficiency (GHD), and chronic GVHD, only in the absence of GVHD in our patients is conspicuous. [3] [4] [5] 7 Taskinen et al found chronic GVHD to be the factor most strongly associated with insulin resistance. 2 Further, Baker et al reported that survivors of allo-SCT were 3.65 times more likely to report diabetes mellitus than their siblings, whereas recipients of auto-SCT showed no difference from their siblings. 6 Chronic GVHD may represent a state of persistent inflammation, which could promote insulin resistance. 23, 24 In the present study, high sensitivity C-reactive protein was elevated in the patient group, even after adjustment for fat mass. We are not aware of any similar data from patients with chronic GVHD.
Recent data from the Childhood Cancer Survivor Study show that patients treated with TBI were 7.2 times more likely to report diabetes mellitus after adjustment for factors that are associated with diabetes mellitus, including BMI. 7 In a study by Hoffmeister et al, only two of the 32 subjects diagnosed with type 2 diabetes mellitus were obese and in that by Neville et al BMIs were similar in childhood cancer survivors and controls. 3, 25 Only Chemaitilly et al reported an association between overweight/obesity and insulin resistance. 8 In most studies, the high prevalence of disturbed glucose homeostasis after SCT thus appears to be independent of overweight/obesity as defined by BMI. 9 The lack of association between disturbed glucose homeostasis and obesity after TBI has sparked speculation about alternative causes, including radiation-induced b-cell dysfunction or dysregulation of GH and/or adipokine secretion. 7 Although none of the patients in the present study had diabetes mellitus and most of our patients with insulin resistance were indeed overweight when assessed using BMI, our data indicate that the importance of body composition after SCT may be underestimated when assessed using BMI alone. Thus, BMI tended to be lower in the patient group due to the lower lean body mass, whereas percentage fat mass was higher among the patients and was associated with decreased insulin sensitivity. Second, most patients with insulin resistance following TBI were centrally obese, indicating an increase in visceral adipose tissue, which is considered to be the more metabolically active fat and is strongly associated with insulin resistance. 2, 3, 8, 26 Thus, fat mass and its distribution are certainly crucial and future studies on SCT survivors should include valid measurements of body composition.
What, then, causes the adverse body composition that promotes insulin resistance following SCT? Taskinen et al reported an association between GHD and the clustering of abdominal obesity, insulin resistance and hypertriglyceridemia. 5 GHD, often of lesser degrees, is common after TBI. [27] [28] [29] [30] Murray et al reported that, for various reasons (not including SCT), young adults with lesser degrees of impaired GH secretion had significant abnormalities of body composition characteristic of GHD (increased fat mass, low lean body mass and central obesity), but of intermediate severity between severe GHD and healthy controls. 31 In the present study, lower GH secretion and a higher percentage fat mass were associated with longer follow-up, which suggest inverse changes over time. Interpretation of the data is difficult, as overweight/obesity may lead to low GH secretion in endocrinologically healthy individuals. That said, we think it is plausible that longstanding GHD may be important for the development of an adverse body composition, which may promote a state of insulin resistance. Eventually, this may lead to the development of the metabolic syndrome, the core signs of which (hyperinsulinemia and hypertriglyceridemia combined) was found in 9 out of the 23 (39%) SCT survivors in the study by Taskinen et al. 2, 32 Another possible cause of insulin resistance is that irradiation may result in altered secretion of, or resistance to, adipokines. 33 Leptin levels correlate and adiponectin levels inversely correlate with fat mass. Interestingly, we found a higher level of leptin and a lower level of adiponectin in the patients, also after adjustment for fat mass. Hypothetically, hyperleptinemia in our patients may be due to primary hypersecretion and hypoadiponectinemia to hyposecretion following irradiation to the adipocytes. Hyperleptinemia may also be secondary to irradiationinduced central insensitivity and/or GHD. 34 Although we found no correlation between leptin or adiponectin and insulin sensitivity in the present small study, hyperleptinemia and hypoadiponectinemia have been reported to be related to insulin resistance in many other settings and should be included in larger SCT studies. 11, 12 Weaknesses of the study include the small sample size and its cross-sectional design, limiting the possibility to determine the impact of potential etiological factors, including cranial radiation, GH deficiency and untreated hypogonadism, on the outcomes. The fact that 7 of the 25 of the eligible survivors chose not to participate may also have introduced a selection bias. There was a disproportionately large number of males who declined participation and the non-participants had a potentially longer follow-up time. However, we are not aware of any sex difference in the propensity to develop insulin resistance and/or disturbed glucose homeostasis after SCT. Further, the lack of a relationship between follow-up time and sensitivity and disposition indices in the present study implies that a few years longer follow-up would not have made a significant difference.
In summary, we found evidence of decreased insulin sensitivity under both basal conditions and under conditions of insulin stimulation, but no evidence of b-cell dysfunction median 18 years after TBI. In comparison with healthy controls, the patients had abnormalities in body composition with a proportionally higher fat mass, which was associated with decreased insulin sensitivity. We therefore propose that the decreased insulin sensitivity may be explained by adverse body composition following SCT. The adverse body composition may in turn owe partially to long-standing GH deficiency. Hyperleptinemia and hypoadiponectinemia may also be involved in the development of decreased insulin sensitivity.
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